{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123340","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.630762+00:00","generated_at":"2026-05-30T03:43:37.226363+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nkarta Q3 net loss $28.3M; cash $405.3M; drops NHL, focuses NKX019 on autoimmune","bullets":["Net loss of $28.3M ($0.39 per basic/diluted share) for Q3 2024; cash, equivalents, investments $405.3M.","First patient dosed in Ntrust-1 (lupus nephritis) and CUIMC IST (SLE); enrollment ongoing.","Ntrust-2 (systemic sclerosis, myositis, vasculitis) enrollment expected by year-end 2024; preliminary data in 2025.","Forgoes further NKX019 development in non-Hodgkin lymphoma; no new NHL trials planned.","Current cash expected to fund operations into late 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123340","json":"https://secwatch.observer/filing/0000950170-24-123340.json","markdown":"https://secwatch.observer/filing/0000950170-24-123340.md","text":"https://secwatch.observer/filing/0000950170-24-123340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024123340/0000950170-24-123340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024123340/nktx-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:43:37.226363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}